Venlafaxine에 의한 급성 독성 간염 1예

참고문헌 (34)

1. Holliday SM, "Venlafaxine. A review of its pharmacology and therapeutic potential in depression", Drugs, 49, pp.280~294 (1995)
2. Rotzinger S, "Metabolism of some “second”- and “fourth”-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine", Cell Mol Neurobiol, 19, pp.427~442 (1999)
3. Courtney DB, "Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials", Can J Psychiatry, 49, pp.557~563 (2004)
4. Rudolph RL, "Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors", Acta Psychiatr Scand Suppl, pp.24~30 (2002)
5. Dierick M, "A review of the efficacy and tolerability of venlafaxine", Eur Psychiatry, 12(4), pp.307s~313s (1997)
6. Bradley RH, "Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder", Am J Ther, 10, pp.318~323 (2003)
7. Lithner F, "Venlafaxine in treatment of severe painful peripheral diabetic neuropathy", Diabetes Care, 23, pp.1710~1711 (2000)
8. Pernia A, "Venlafaxine for the treatment of neuropathic pain", J Pain Symptom Manage, 19, pp.408~410 (2000)
9. Horst WD, "Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion", J Affect Disord, 51, pp.237~254 (1998)
10. Rudolph RL, "The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database", J Clin Psychopharmacol, 16, pp.54S~61S (1996)
11. Cardona X, "Venlafaxine-associated hepatitis", Ann Intern Med, 132, pp.417~ (2000)
12. Horsmans Y, "Venlafaxine-associated hepatitis", Ann Intern Med, 130, pp.944~ (1999)
13. Phillips BB, "Hepatitis associated with lowdose venlafaxine for postmenopausal vasomotor symptoms", Ann Pharmacother, 40, pp.323~327 (2006)
14. Pradeep RJ, "Venlafaxine induced hepatitis", J Assoc Physicians India, 52, pp.340~ (2004)
15. Sencan I, "Low-dose venlafaxine-associated liver toxicity in chronic hepatitis", Ann Pharmacother, 38, pp.352~353 (2004)
16. Detry O, "Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report", ransplant Proc, 41, pp.3435~3436 (2009)
17. Ostapowicz G, "Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States", Ann Intern Med, 137, pp.947~954 (2002)
18. Lee WM, "Acute liver failure in the United States", Semin Liver Dis, 23, pp.217~226 (2003)
19. Temple RJ, "Safety of newly approved drugs: implications for prescribing", JAMA, 287, pp.2273~2275 (2002)
20. Kaplowitz N, "Drug-induced liver disorders: implications for drug development and regulation", Drug Saf, 24, pp.483~490 (2001)
21. Chitturi S, "Herbal hepatotoxicity: an expanding but poorly defined problem", J Gastroenterol Hepatol, 15, pp.1093~1099 (2000)
22. Kaplowitz N, "Causality assessment versus guilt-by-association in drug hepatotoxicity", Hepatology, 33, pp.308~310 (2001)
23. Lee WM, "Drug-induced hepatotoxicity", N Engl J Med, 349, pp.474~485 (2003)
24. Andrade RJ, "Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists", World J Gastroenterol, 13, pp.329~340 (2007)
25. Danan G, "Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries", J Clin Epidemiol, 46, pp.1323~1330 (1993)
26. 김동준, "독성 간손상의 평가", 대한소화기학회지, 53(1), pp.5~14 (2009), 대한소화기학회
27. Sadock BJ, "Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. 8th ed", pp.2781~2788 (2005), Lippincott Williams & Wilkins
28. Russmann S, "Current concepts of mechanisms in drug-induced hepatotoxicity", Curr Med Chem, 16, pp.3041~3053 (2009)
29. Ereshefsky L, "Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine", Depress Anxiety, 12(1), pp.30~44 (2000)
30. Shams ME, "CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine", J Clin Pharm Ther, 31, pp.493~502 (2006)
31. Preskorn S, "Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers", J Clin Psychopharmacol, 29, pp.39~43 (2009)
32. Puozzo C, "Pharmacology and pharmacokinetics of milnacipran", Int Clin Psychopharmacol, 17(1), pp.S25~S35 (2002)
33. Skinner MH, "Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers", Clin Pharmacol Ther, 73, pp.170~177 (2003)
34. Vuppalanchi R, "Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network", Aliment Pharmacol Ther, 32, pp.1174~1183 (2010)[DOI]

관련 논문AI추천